# Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

> **NCT00007891** · PHASE1 · COMPLETED · sponsor: **Cancer Research Institute of Contra Costa**

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **PROCEDURE:** autologous bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** indium In 111 monoclonal antibody BrE-3
- **RADIATION:** yttrium Y 90 monoclonal antibody BrE-3

## Key facts

- **NCT ID:** NCT00007891
- **Lead sponsor:** Cancer Research Institute of Contra Costa
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-06
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00007891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00007891, "Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00007891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*